Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPDC-T Cells Combined with Anti-HBV Drugs in Chronic Hepatitis B
NCT02615639Phase 2Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Nov 2015
- Primary completion
- Nov 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 2, randomised, open-label trial of HPDC-T cells in Chronic Hepatitis B (CHB) (6 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Hepatitis B surface Antigen (HBeAg) seroconversion at 3 years. Status: unknown.
02
Drugs
HPDC-T cells
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02615639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02615639.